1. Home
  2. TNYA vs HURA Comparison

TNYA vs HURA Comparison

Compare TNYA & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tenaya Therapeutics Inc.

TNYA

Tenaya Therapeutics Inc.

HOLD

Current Price

$0.80

Market Cap

181.5M

Sector

Health Care

ML Signal

HOLD

Logo TuHURA Biosciences Inc.

HURA

TuHURA Biosciences Inc.

HOLD

Current Price

$2.26

Market Cap

160.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
TNYA
HURA
Founded
2016
2009
Country
United States
United States
Employees
N/A
22
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
181.5M
160.5M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
TNYA
HURA
Price
$0.80
$2.26
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
2
Target Price
$5.33
$9.50
AVG Volume (30 Days)
2.7M
731.4K
Earning Date
05-07-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
54.96
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.53
$0.41
52 Week High
$2.35
$3.90

Technical Indicators

Market Signals
Indicator
TNYA
HURA
Relative Strength Index (RSI) 50.07 46.13
Support Level $0.65 $2.14
Resistance Level $0.80 $2.80
Average True Range (ATR) 0.07 0.19
MACD 0.00 -0.02
Stochastic Oscillator 39.32 29.00

Price Performance

Historical Comparison
TNYA
HURA

About TNYA Tenaya Therapeutics Inc.

Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.

About HURA TuHURA Biosciences Inc.

TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.

Share on Social Networks: